


10/550175

CERTIFICATE OF EXPRESS MAILING	
NUMBER: EV 691738418 US	JC17 Rec'd PCT/PTO 21 SEP 2005
DATE OF DEPOSIT: September 21, 2005	
I hereby certify that this paper or fee is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
 Paula S. Linkhart	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Stany DEPRAETERE

Katrien LORRÉ

Marie-Ange BUYSE

Group Art Unit:

Examiner:

Serial No.:

Atty. Dkt. No.: **11362.0043.PCUS01**

Filed:

For: **TREATMENTS OF TYPE 1 IMMUNE
RESPONSE-MEDIATED
INFLAMMATORY LUNG DISEASE BY
MODULATION OF IFN-GAMMA
ACTIVITY**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria VA, 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record.

The present application is a §371 national application of PCT Application No. PCT/US2004/050375 filed March 26, 2004. The PCT Application is relied upon for an earlier filing date under 35 U.S.C. § 120. In accordance with Rule 37 C.F.R. § 1.98(d), a copy of the listed

JC17 Rec'd PC7/PTO 21 SEP 2005

documents B1-B3 and C1-C7 are not enclosed as they had been previously cited by or submitted to the U.S. Patent and Trademark Office in the International Search Report mailed September 2, 2004.

In accordance with 37 C.F.R §§ 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any additional fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Deposit Account No. 01-2508/11362.0043.PCUS01.

Applicant respectfully requests that the listed documents be made of record in the present case.

Respectfully submitted,



Patricia A. Kammerer
Reg. No. 29,775
Attorney for Assignee
Innogenetics N.V.

Customer No. 23,369
HOWREY LLP
1111 Louisiana, 25th Floor
Houston, Texas 77002-5242
Phone: 713.787.1400
Fax: 713.787.1440

Date: September 21, 2005

Form PTO-1449 (modified)	Atty. Docket No. 11362.0043.PCUS01	Serial No.
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Stany DEPRAETERE; Katrien LORRÉ; Marie-Ange BUYSE	
	Filing Date:	Group:
U.S. Patent Documents <i>See Page 1</i>	Foreign-Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1						

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	WO 02/069996	09/12/2002	WIPO			
	B2	WO 01/34180	05/17/2001	WIPO			
	B3	WO 95/05849	03/02/1995	WIPO			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Denis M et al., "MURINE Hypersensitivity Pneumonitis Bidirectional Role of Interferon-Gamma", <i>Clinical and Experimental Allergy</i> , 22(8): 783-792 (1992).
	C2	Zhongde Wang et al., "Interferon Gamma Induction of Pulmonary Emphysema in the Adult Marine Lung," <i>J. of Exp. Med.</i> , 192(11): 1587-1599 (2000).
	C3	Iben Dalum et al. "Therapeutic Antibodies Elicited by Immunization Against TNF-Alpha," <i>Nature Biotechnology</i> , 17:666-669 (1999).
	C4	Guy Froyen et al., "Potential Therapeutic Use of Antibodies Directed Towards HuIFN-Gamma," 10:49-57 (1997).
	C5	Arnaldo Caruso et al., "Natural Antibodies to IFN-Gamma in Man and Their Increase During Infection," <i>The Journal of Immunology</i> , 144:685-690 (1990).
	C6	Bruce W.S. Robinson et al., "Gamma Interferon is Spontaneously Released by Alveolar Macrophages and Lung T Lymphocytes in Patients with Pulmonary Sarcoidosis," <i>The Journal of Clinical Investigation, Inc.</i> 75:1488-1495 (1985).
	C7	Beers-MH and Berkow-R, "The Merck Manual of Diagnosis and Therapy," <i>Merck Research Laboratories</i> , p.268, right-hand column, last paragraph (1999).

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)